Solid Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Schwartz from Leerink Partners reiterated a Buy rating on the stock and has a $20.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Schwartz has given his Buy rating due to a combination of factors highlighting Solid Biosciences’ promising advancements in their gene therapy programs. The company is making significant headway in its dosing for SGT-003 in Duchenne muscular dystrophy, aiming to enroll 28-30 patients by early 2026. This progress positions them well for upcoming discussions with the FDA regarding Phase 3 study design and potential accelerated approval pathways.
Additionally, Solid Biosciences is advancing its pipeline with the initiation of Phase 1b studies for SGT-212 in Friedreich’s ataxia and SGT-501 in CPVT, with patient dosing set to begin in early 2026. These developments suggest potential safety and progress updates by the end of 2026, which could serve as key inflection points for the company’s stock. Given these strategic advancements and the unmet needs in their target disease areas, Schwartz reiterates a $20 price target and an Outperform rating for Solid Biosciences.
Schwartz covers the Healthcare sector, focusing on stocks such as Fulcrum Therapeutics, Wave Life Sciences, and uniQure. According to TipRanks, Schwartz has an average return of 34.4% and a 55.40% success rate on recommended stocks.
In another report released on December 4, Needham also initiated coverage with a Buy rating on the stock with a $16.00 price target.